TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a clinical diagnosis of stable plaque psoriasis involving a minimum of 2% and no more than 12% affected body surface area.~* Subject has an Investigator's Global Assessment (IGA) score of at least three (moderate) at study start.~* If subject is a woman of childbearing potential, she must have a negative urine pregnancy test and agree to use an effective form of birth control for the duration of the study.~Exclusion Criteria:~* Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.~* Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.~* Subject has a physical condition which, in the investigator's opinion, might impair evaluation of plaque psoriasis, or which exposes the subject to an unacceptable risk by study participation.~* Subject has used any phototherapy (including laser), photo-chemotherapy or other forms of photo based therapy for the treatment of their psoriasis within 30 days prior to study start.~* Subject has used any systemic methotrexate, retinoids, systemic corticosteroids \[including intralesional, intra-articular, and intramuscular corticosteroids\], cyclosporine or analogous products within 90 days prior to study start.~* Subject has used any systemic biologic therapy (i.e., FDA-approved or experimental therapy) within five half-lives of the biologic prior to study start.~* Subject had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to study start or is intending to have such exposure during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 122-0551 Foam (Type: EXPERIMENTAL): 122-0511 Foam, topically applied twice daily
- Vehicle Foam (Type: PLACEBO_COMPARATOR): Vehicle Foam, topically applied twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males/females 13-17 years of age meeting DSM-IV criteria for a primary diagnosis of ADHD~Exclusion Criteria:~* Controlled or uncontrolled comorbid psychiatric diagnosis (except ODD) with significant symptoms such as PTSD, psychosis, bipolar disease, severe OCD~* Known non-responder to stimulant medication~* Documented allergy or intolerance to ADDERALL, ADDERALL XR or amphetamines~* Conduct Disorder, hypertension, history of seizure~* Tic disorder or Tourette's disorder

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Adderall XR (10 mg) (Type: EXPERIMENTAL): None
- Adderall XR (20 mg) (Type: EXPERIMENTAL): None
- Adderall XR (30 mg) (Type: EXPERIMENTAL): None
- Adderall XR (40 mg) (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Male or female patient who had endothelial keratoplasty procedure within the past 1 to 7 weeks~* Patient is able and willing to administer eye drops~* Patient is able to comprehend and has signed the Informed Consent form.~* Patient is likely to complete the one-year course of the study~Exclusion Criteria:~* A history of a previous rejection episode in the study eye~* A patient exhibiting intraocular inflammation~* A patient with a known sensitivity to any of the ingredients in the study medications~* A patient who has a condition (i.e., UNCONTROLLED systemic disease) or is in a situation which in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study~* A patient with abnormal eyelid function.~* A patient that is exhibiting active corneal ulceration, keratitis, or conjunctivitis, or who has a history of herpetic keratitis.~* Presence of any ocular disease that would interfere with the evaluation of the study treatment. However, patients with a history of cystoid macular edema, age-related macular degeneration, controlled glaucoma, corneal neovascularization, and other non-interfering comorbidities may be enrolled.~* A patient with a history of non-compliance with using prescribed medication.~* A patient who is concurrently involved in or participated in another randomized clinical trial within 30 days prior to enrollment in this study.~* Patients who are pregnant or planning to become pregnant within the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Loteprednol (Type: ACTIVE_COMPARATOR): Loteprednol etabonate 0.5% gel applied topically 4 times daily for 2 months, 3 times daily for 1 month, twice daily for one month and once daily for 7 months
- Prednisolone acetate (Type: ACTIVE_COMPARATOR): Prednisolone acetate 1% ophthalmic solution applied 4 times daily for two months, 3 times daily for one month, twice daily for one month, and once daily for 7 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Cytologic of histologic proof of pancreatic ductal carcinoma~* No evidence of metastatic disease~* 18 years of age or older~* ECOG Performance Status of 0 or 1 - Lab values as outlined in the protocol~Exclusion Criteria:~* Tumors in the body or tail of the pancreas~* Hepatic or peritoneal metastases detected by imaging or laparoscopy prior to chemoradiation~* Serious concomitant systemic disorders incompatible with the study, such as significant cardiac or pulmonary morbidity, ongoing infection as manifested by fever~* Pregnant or lactating women~* Life expectancy of \< 3 months~* Serious, uncontrolled, concurrent infection (s)~* Prior chemotherapy or radiation for treatment of the patient's pancreatic tumor~* Clinically significant cardiac disease or myocardial infarction within the last 12 months~* Other serious uncontrolled medical condition that the investigator feels might compromise study participation~* Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome~* Known, existing uncontrolled coagulopathy~* Any prior fluoropyrimidine therapy~* Prior unanticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to a 5-fluorouracil or known DPD deficiency~* Participation in any investigational drug study within 4 weeks preceding the start of the study~* History of uncontrolled seizures, central nervous system disorders or psychiatric disability~* Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recovery~* Patients on cimetidine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): 10 Radiation Sessions over 2 weeks
- Group 2 (Type: EXPERIMENTAL): 5 Radiation sessions: 3 in week 1 and 2 in week 2
- Group 3 (Type: EXPERIMENTAL): 5 Radiation sessions: 4 in week 1 and 1 in week 2
- Group 4 (Type: EXPERIMENTAL): 5 Radiation Sessions in one week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed PC with malignant ascites.~* Karnofsky Performance Status (KPS) score ≥60%.~* Normal function of bone marrow.~* Predicted survival time \>1 month.~* Written informed consent.~Exclusion Criteria:~* Surgery within 3 weeks or not full recovery of postoperative suture.~* Active bleeding or vascular occlusion in the mEHT treatment area.~* Emotional instability.~* Impossibility to place the patient into the mEHT machine.~* Metallic implants or replacements in the treatment area.~* Electronic implanted devices anywhere.~* Missing or damaged heat-sense nerves or other field-sensitive issues in the treatment area.~* Very low white blood cell count (\<1.5×10(9)/L), agranulocytosis (\<0.5×10(9)/L) or severe anemia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Study Group (Type: EXPERIMENTAL): Modulated Electro-Hyperthermia (mEHT): 150 Watt x 60 min/session every 2nd day for 4 weeks (14 sessions); TCM Herbal Decoction: Shi Pi Decoction administered orally twice a day (200 mL x 2) 30 min after breakfast and supper, for 4 weeks.
- Control Group (Type: ACTIVE_COMPARATOR): IPCI: CDDP (30-60 mg) with 5FU (500-600 mg/sqm of body surface), both dissolved in 100 mL of normal saline, after abdominal paracentesis and catheterization with following closed drainage of the ascites up to small amount of remaining liquid. After IPCI, the catheter occluded. Administered biweekly during four weeks of the course, totally two times.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age below 18 years~* Neonatal diabetes secondary to documented mutation in one of the 2 sub units of potassium channels~* Patients already treated by glibenclamide pills~* Signed consent~Exclusion Criteria:~* Families unable to fill in the questionnaries~* Patients unable to answer to the visual hedonic squale~* Patients unable to take the oral solution~* Known allergy to sulfonylureas or to other antidiabetic or antibiotic sulfamides~* Insulin therapy associated to glibenclamide~* Miconazole therapy~* Porphyria~* Breast feeding~* Severe renal failure (creatinine clearance below 30 ml/mn)~* Liver failure (prothombine time below 70)~* Not affiliated to the health care system

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Patients with neonatal diabetes (Type: EXPERIMENTAL): Patients with neonatal diabetes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Current history of SBS as a result of major intestinal resection, (eg, due to necrotizing enterocolitis, midgut volvulus, intestinal atresia, or gastroschisis) for at least 12 months prior to screening~* Short bowel syndrome that requires parenteral nutrition/intravenous (PN/IV) support~* Stable PN/IV support for at least 3 months prior to enrollment based upon the opinion of the investigator~Key Exclusion Criteria:~* Serial transverse enteroplasty or any other bowel lengthening procedure performed within the past 3 months~* Unstable absorption due to cystic fibrosis, untreated Hirschsprung's disease or known DNA abnormalities (ie, Familial Adenomatous Polyposis, Fanconi syndrome)~* Evidence of obstruction on upper gastrointestinal (GI) series done within 6 months prior to screening~* Major gastrointestinal surgical intervention within 3 months prior to screening (insertion of feeding tube or endoscopic procedure is allowed)

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- teduglutide (Type: EXPERIMENTAL): Open label teduglutide, subcutaneously injected.
- Standard of Care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 18 years or older~* Must have a suspected or proven infection~* Must have two or more sepsis-associated organ dysfunctions~Exclusion Criteria:~* Documented multiple organ dysfunction greater than 24 hours prior to start of study drug~* Actual body weight less than 30 kg or more than 135 kg~* Platelet count less than 30,000/mm\^3~* Active internal bleeding or at increased risk of bleeding~* Not expected to survive 28 days given the patient's pre-existing uncorrectable medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard therapy (Type: EXPERIMENTAL): 24 microgram/kilogram/hour (mcg/kg/hr) for 24 hours, followed by 24 mcg/kg/hr for an additional 72 hours
- Alternative therapy:moderate protein C deficiency (Type: EXPERIMENTAL): 24 mcg/kg/hr for 24 hours, followed by 24 mcg/kg/hr for an additional 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
- Alternative therapy:severe protein C deficiency (Type: EXPERIMENTAL): 24 mcg/kg/hr for 24 hours, followed by 30 or 36 mcg/kg/hr for 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LIPS-B: Lung Injury Prevention Study With Budesonide and Beta

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (age \> 18)~* Admitted to the hospital through the emergency department (ED)~* High risk of developing ARDS (Lung Injury Prediction Score (LIPS) greater than or equal to four)~Exclusion Criteria:~* Inhaled corticosteroid and/or beta agonist treatment on admission or within 7 days prior to admission (history of asthma or COPD necessitating therapy)~* Chronic pulmonary disease requiring daytime oxygen supplementation therapy~* Systemic steroid treatment on admission or within 7 days prior to admission equivalent to more than 5 mg of prednisone daily~* Inability to obtain consent within 12 hours of hospital presentation~* Acute lung injury prior to randomization~* Receiving mechanical ventilation before current hospital admission (patient who is ventilator dependent)~* Presentation believed to be purely due to heart failure without other known risk factors for ARDS~* Allergy or other contraindication to either budesonide and/or formoterol use~* Expected hospital stay and/or survival \<48 hours or admission for comfort or hospice care~* Patient, surrogate or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)~* Previous enrollment in this trial.~* Co-enrollment with LIPS-A trial is not allowed.~* An active enrollment in other concomitant trial will be judged on case by case basis by PIs of both trials.~* EKG and/or clinical presentation suggestive of acute coronary ischemia~* New onset cardiac arrhythmia~* Current atrial fibrillation with ventricular rate of \>110/minute~* Persistent sinus tachycardia of \>130/minute despite early goal directed therapy with fluids, pressors, antibiotics and supplemental oxygen~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Budesonide and Formoterol (Type: EXPERIMENTAL): Subjects randomized to this arm will receive combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) twice daily, with at least 6 hours between doses, for 5 days for a total of 10 doses or until hospital discharge or death, with the first dose administered as soon as possible following randomization but not later than 4 hours.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to this arm will receive normal saline, the quantity, appearance and timing of the doses the same as the intervention arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of TA : ACR and /or Ishikawa modified Sharma criteria of TA~* Age of 18 years or older~* Willing to use an effective means of birth control throughout the study~Exclusion Criteria:~* Patients immunosuppressive treatment or biologics other than steroids 4 months before~* Evidence of active infection (including chronic infection)~* HIV infected, hepatitis C infected, or a positive hepatitis B surface antigen~* History of any malignant neoplasm except adequately treated basal or squamous cell carcinoma of the skin or solid tumors treated with curative therapy and disease-free for at least 5 years~* Inability to provide informed consent~* Cytopenia, as defined by platelet count \< 100 × 109/L (100,000/mm3), hemoglobin \< 85 g/L (8.5 g/dL; 5.3 mmol/L), absolute neutrophil count \< 2.0 × 109/L (2000/mm3), absolute lymphocyte count \< 0.5 × 109/L (500/mm3)~* Insufficient liver function~* Insufficient kidney function, as defined by a serum creatinine of more than 3 mg/dL or creatinine clearance of 20 ml/min or less~* Positive tuberculin skin test and/or positive Quantiferon~* Radiographic evidence suggestive of tuberculosis~* Contraindication to and precaution in use of Tocilizumab according to the summary product description~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- TOCILIZUMAB MONTHLY DURING 6 (Type: EXPERIMENTAL): intravenous injection, 8 mg/kg, monthly during 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* You must be 18 to 65 years old.~* You must have a diagnosis of bipolar I disorder and must be experiencing a manic or mixed (symptoms of mania and depression occurring together) episode.~* You must be able to visit the doctor's office as scheduled for 15 weeks.~* All female patients must test negative for pregnancy and, if of childbearing potential, must be using a medically accepted means of contraception.~Exclusion Criteria:~* You have rapid cycling bipolar disorder, or are having hallucinations or delusions, or are feeling suicidal.~* You are pregnant or breastfeeding~* You have a history of: inadequately controlled diabetes; heart disease; narrow angle glaucoma; low white blood cell or platelet count; have a positive test result for human immunodeficiency virus (HIV+); or any other serious, unstable illnesses as judged by the study physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* eligibility to stem cell transplantation~Exclusion Criteria:~* allergy to Zinc~* copper deficiency or Wilson's syndrome~* patients who admit zinc assumption in other drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation
- Zinc (Type: EXPERIMENTAL): patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete